SCHEMBL20132293

SCHEMBL20132293

CC(C)(C)OC(=O)Nc1cccc(NC(=O)c2ccc(C=O)cc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 2/20 0.56
▸ HDAC3 O15379 2/20 0.54
▸ HDAC8 Q9BY41 2/20 0.54
▸ HDAC6 Q9UBN7 2/20 0.54
▸ HDAC1 Q13547 1/20 0.54
▸ HDAC2 Q92769 1/20 0.54
▸ KCNK9 Q9NPC2 4/20 0.52
▸ KCNK3 O14649 5/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ CYP17A1 P05093 1/20 0.47
▸ RXFP1 Q9HBX9 1/20 0.46
▸ TP53 P04637 3/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ THRB P10828 1/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ SNCA P37840 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23899079 0.91 NAMPT (0.65) NAMPTHDAC3HDAC8HDAC6HDAC1
SCHEMBL20132041 0.86 HDAC3 (0.52) NAMPTHDAC3HDAC8HDAC6HDAC1
SCHEMBL23899175 0.84 KCNK3 (0.64) NAMPTKCNK9KCNK3KMT2AMEN1
SCHEMBL29488493 0.84 HDAC3 (0.54) NAMPTHDAC3HDAC8HDAC6HDAC1
SCHEMBL694391 0.84 HDAC3 (0.54) NAMPTHDAC3HDAC8HDAC6HDAC1
SCHEMBL27493988 0.83 HDAC8 (0.47) NAMPTHDAC3HDAC8HDAC6HDAC1
SCHEMBL20132007 0.83 HDAC3 (0.58) NAMPTHDAC3HDAC8HDAC6HDAC1
SCHEMBL20132172 0.83 HDAC3 (0.50) NAMPTHDAC3HDAC8HDAC6HDAC1
SCHEMBL29029431 0.82 HDAC3 (0.56) NAMPTHDAC3HDAC8HDAC6HDAC1
SCHEMBL1065454 0.82 F10 (0.49) NAMPTHDAC1KMT2AMEN1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220354959-A1 GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF ABBVIE INC. (US) 2022-11-10 — — US disclosed
EP-3901162-A1 GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF AbbVie Inc. (US) 2021-10-27 — — EP disclosed
CN-109476699-B Glucocorticoid receptor agonists and immunoconjugates thereof 艾伯维公司 2021-10-12 — — CN disclosed
US-20200338208-A1 GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF ABBVIE INC. (US) 2020-10-29 — — US disclosed
US-10668167-B2 Glucocorticoid receptor agonist and immunoconjugates thereof ABBVIE INC. (US) 2020-06-02 — — US disclosed
US-20190262465-A1 GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF ABBVIE INC. (US) 2019-08-29 — — US disclosed
US-20180126000-A1 GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF ABBVIE INC. (US) 2018-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180126000-A1 GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF NR3C1, NR3C2, MC2R NAMPT 4467/4885HDAC3 1200/4885HDAC8 1420/4885
US-20200338208-A1 GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF NR3C1, NR3C2, MC2R NAMPT 4467/4885HDAC3 1200/4885HDAC8 1420/4885
US-10668167-B2 Glucocorticoid receptor agonist and immunoconjugates thereof NR3C1, NR3C2, MC2R NAMPT 4467/4885HDAC3 1200/4885HDAC8 1420/4885
US-20190262465-A1 GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF NR3C1, NR3C2, MC2R NAMPT 4467/4885HDAC3 1200/4885HDAC8 1420/4885
US-20220354959-A1 GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF NR3C1, NR3C2, MC2R NAMPT 4467/4885HDAC3 1200/4885HDAC8 1420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback